SSA
ALLO icon

Schonfeld Strategic Advisors’s Allogene Therapeutics ALLO Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-17,192
Closed -$40.1K – 2010
2024
Q2 		$40.1K Buy
+17,192
New +$50.7K ﹤0.01% 1955
2024
Q1 		– Sell
-35,300
Closed -$113K – 2036
2023
Q4 		$113K Buy
+35,300
New +$100K ﹤0.01% 1607
2023
Q3 		– Sell
-102,285
Closed -$508K – 1741
2023
Q2 		$508K Buy
+102,285
New +$553K ﹤0.01% 1219
2023
Q1 		– Sell
-124,500
Closed -$783K – 2064
2022
Q4 		$783K Sell
124,500
-139,391
-53% -$1.29M 0.01% 1278
2022
Q3 		$2.85M Buy
263,891
+145,491
+123% +$1.98M 0.02% 730
2022
Q2 		$1.35M Buy
118,400
+38,000
+47% +$337K 0.01% 881
2022
Q1 		$732K Buy
+80,400
New +$837K 0.01% 1148
2021
Q4 		– Sell
-40,500
Closed -$1.04M – 2107
2021
Q3 		$1.04M Sell
40,500
-63,779
-61% -$1.51M 0.01% 935
2021
Q2 		$2.72M Buy
+104,279
New +$2.97M 0.03% 623
2019
Q1 		– Sell
-10,000
Closed -$269K – 1035
2018
Q4 		$269K Buy
+10,000
New +$266K 0.01% 857

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Schonfeld Strategic Advisors's ALLO Position: Q3 2024 in Review

Schonfeld Strategic Advisors sold out of Allogene Therapeutics (ALLO) in Q3 2024, closing a stake of 17,192 shares — an estimated $40.1K sold.

Schonfeld Strategic Advisors first reported a position in ALLO in Q4 2018 and held it in 10 quarters. The position peaked at $2.85M in Q3 2022. 156 funds tracked by Wall St. Rank hold ALLO as of Q3 2024.

  • Schonfeld Strategic Advisors reported no remaining Allogene Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 17,192 Allogene Therapeutics shares in Q3 2024, an estimated $40.1K.
  • Schonfeld Strategic Advisors first reported a position in Allogene Therapeutics in Q4 2018 and held it in 10 quarters.
  • Schonfeld Strategic Advisors's Allogene Therapeutics position peaked at $2.85M in Q3 2022.
  • 156 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.